Video

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML

Author(s):

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

Eytan Stein, MD, attending physician in the leukemia service at Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia (AML) and myelodysplastic syndrome.

At the time of the data cut-off, 45 patients with IDH2 mutations were analyzed for response. Overall, by investigator-accessed criteria, 56% of patients responded to therapy, Stein explained.

Responses were comprised of complete remissions (CR; n = 6), CR with incomplete platelet recovery (n = 4), marrow CR (n = 4), CR with incomplete hematologic recovery (n = 1), and partial remissions (n = 10). Responses were durable and lasted for 3 months or longer in the majority of patients.

These findings were from an interim analysis of a phase I trial, Stein emphasized. However, if these results are confirmed in larger trials, it could represent a quantum leap over previous treatments for patients with AML that could potentially lead to durable remissions.

<<<

View more from the 2014 ASH Annual Meeting

Related Videos
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.